-+ 0.00%
-+ 0.00%
-+ 0.00%

Immix Biopharma To Present An Abstract On Its Therapy NXC-201 At The ASH 67th Annual Meeting December 6–9, 2025, In Orlando, Florida

Benzinga·10/07/2025 20:10:39
Listen to the news

Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition to be held December 6-9, 2025, in Orlando, Florida.

About AL Amyloidosis

AL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, and liver, causing heart and renal failure, leading to mortality.

The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 37,270 patients in 2025.

The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research.